{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:46:40Z","timestamp":1788306400268,"version":"build-2803163510"},"reference-count":36,"publisher":"CMA Joule Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["cmajo"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.9778\/cmajo.20210024","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T11:20:14Z","timestamp":1637061614000},"page":"E1005-E1012","source":"Crossref","is-referenced-by-count":7,"title":["Estimating the population health burden of Lyme disease in Ontario, Canada: a microsimulation modelling approach"],"prefix":"10.9778","volume":"9","author":[{"given":"Stephen","family":"Mac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor M.","family":"Pullenayegum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"382","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"2021111603201064000_9.4.E1005.1","unstructured":"Why is CDC concerned about Lyme disease? (Centers for Disease Control and Prevention, Atlanta) reviewed 2021 Jan 13. Availablehttps:\/\/www.cdc.gov\/lyme\/why-is-cdc-concerned-about-lyme-disease.html . accessed 2020 Aug. 3."},{"key":"2021111603201064000_9.4.E1005.2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s12889-019-7069-6","article-title":"Malaria and Lyme disease: the largest vector-borne US epidemics in the last 100 years \u2014 success and failure of public health","volume":"19","author":"Rochlin","year":"2019","journal-title":"BMC Public Health"},{"key":"2021111603201064000_9.4.E1005.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2015.02.010"},{"key":"2021111603201064000_9.4.E1005.4","unstructured":"Lyme disease data tables: historical data (Centers for Disease Control and Prevention, Atlanta) reviewed 2021 May 5. Availablehttps:\/\/www.cdc.gov\/lyme\/stats\/tables.html . accessed 2018 Feb 5."},{"key":"2021111603201064000_9.4.E1005.5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.14745\/ccdr.v44i10a01","article-title":"The continued rise of Lyme disease in Ontario, Canada: 2017","volume":"44","author":"Nelder","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2021111603201064000_9.4.E1005.6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq157"},{"key":"2021111603201064000_9.4.E1005.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2015.02.012"},{"key":"2021111603201064000_9.4.E1005.8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/ciz1158","article-title":"Long-term sequelae and health-related quality of life associated with Lyme disease: a systematic review","volume":"71","author":"Mac","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021111603201064000_9.4.E1005.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.10270"},{"key":"2021111603201064000_9.4.E1005.10","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.4.554"},{"key":"2021111603201064000_9.4.E1005.11","doi-asserted-by":"publisher","DOI":"10.3201\/eid0503.990302"},{"key":"2021111603201064000_9.4.E1005.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707313370525"},{"key":"2021111603201064000_9.4.E1005.13","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170317"},{"key":"2021111603201064000_9.4.E1005.14","unstructured":"(2017) Guidelines for the economic evaluation of health technologies: Canada (Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa), 4th ed, pp 1\u201376."},{"key":"2021111603201064000_9.4.E1005.15","first-page":"e289","article-title":"Lyme disease: knowledge, beliefs, and practices of physicians in a low-endemic area","volume":"58","author":"Henry","year":"2012","journal-title":"Can Fam Physician"},{"key":"2021111603201064000_9.4.E1005.16","unstructured":"For health professionals: Lyme disease (Public Health Agency of Canada, Ottawa) modified 2021 Feb. 8. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/lyme-disease\/health-professionals-lyme-disease.html . accessed 2021 Apr. 19."},{"key":"2021111603201064000_9.4.E1005.17","unstructured":"Lyme disease \u2014 Serology (Public Health Ontario, Toronto) updated July 2020, Available: https:\/\/www.publichealthontario.ca\/en\/laboratory-services\/test-information-index\/lyme-disease-serology . accessed 2020 Sept. 23."},{"key":"2021111603201064000_9.4.E1005.18","doi-asserted-by":"crossref","first-page":"e0168613","DOI":"10.1371\/journal.pone.0168613","article-title":"The accuracy of diagnostic tests for Lyme disease in humans, a systematic review and meta-analysis of north American research","volume":"11","author":"Waddell","year":"2016","journal-title":"PLoS One"},{"key":"2021111603201064000_9.4.E1005.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199208203270806"},{"key":"2021111603201064000_9.4.E1005.20","first-page":"S46","article-title":"Randomized trial of doxycycline vs. amoxicillin\/probenecid for the treatment of Lyme arthritis: treatment of non-responders with intravenous penicillin or ceftriaxone","volume":"32","author":"Liu","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2021111603201064000_9.4.E1005.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500140064037"},{"key":"2021111603201064000_9.4.E1005.22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1212\/WNL.42.2.303","article-title":"Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease","volume":"42","author":"Logigian","year":"1992","journal-title":"Neurology"},{"key":"2021111603201064000_9.4.E1005.23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(88)92011-9","article-title":"Treatment of late Lyme borreliosis \u2014 randomised comparison of ceftriaxone and penicillin","volume":"1","author":"Dattwyler","year":"1988","journal-title":"Lancet"},{"key":"2021111603201064000_9.4.E1005.24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.7.1203"},{"key":"2021111603201064000_9.4.E1005.25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/zph.12560","article-title":"Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: a population-based matched cohort study using health administrative data","volume":"66","author":"Shing","year":"2019","journal-title":"Zoonoses Public Health"},{"key":"2021111603201064000_9.4.E1005.26","first-page":"E102","article-title":"Estimating health burden attributable to laboratory-confirmed Lyme disease in Ontario, Canada: a population-based matched cohort study using health administrative data","volume":"40","author":"Mac","year":"2020","journal-title":"Med Decis Making"},{"key":"2021111603201064000_9.4.E1005.27","doi-asserted-by":"publisher","DOI":"10.1086\/508667"},{"key":"2021111603201064000_9.4.E1005.28","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.23.100901.140513"},{"key":"2021111603201064000_9.4.E1005.29","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454577"},{"key":"2021111603201064000_9.4.E1005.30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fmed.2017.00224","article-title":"The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome","volume":"4","author":"Rebman","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"2021111603201064000_9.4.E1005.31","doi-asserted-by":"publisher","DOI":"10.1086\/521256"},{"key":"2021111603201064000_9.4.E1005.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2013.09.002"},{"key":"2021111603201064000_9.4.E1005.33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198509"},{"key":"2021111603201064000_9.4.E1005.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044103"},{"key":"2021111603201064000_9.4.E1005.35","unstructured":"About the network (Canadian Lyme Disease Research Network), Available: https:\/\/www.clydrn.ca\/about-the-network\/# . accessed 2021 Apr. 19."},{"key":"2021111603201064000_9.4.E1005.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fmed.2020.00057","article-title":"Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease","volume":"7","author":"Rebman","year":"2020","journal-title":"Front Med (Lausanne)"}],"container-title":["CMAJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.9778\/cmajo.20210024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T11:21:15Z","timestamp":1637061675000},"score":1,"resource":{"primary":{"URL":"http:\/\/cmajopen.ca\/lookup\/doi\/10.9778\/cmajo.20210024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,16]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.9778\/cmajo.20210024"],"URL":"https:\/\/doi.org\/10.9778\/cmajo.20210024","relation":{},"ISSN":["2291-0026"],"issn-type":[{"value":"2291-0026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}